Author

K. Pavic

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 3 Approach:experimental assay· 3 Organism:human· 3 Research Focus:clustering· 2 Research Focus:drug response / drug discovery· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

A. Gaigneaux· 2 shared D. K. Abankwa· 2 shared G. b. Manoharan· 2 shared A. Kiriazis· 1 shared A. Yeste-Vazquez· 1 shared C. L. Steffen· 1 shared C. Lucas· 1 shared E. Glaab· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

A. Gaigneaux

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Identification of an H-Ras nanocluster disrupting peptide

G. b. Manoharan, C. L. Steffen, K. Pavic, A. Yeste-Vazquez, M. Knuuttila, N. Arora, Y. Zhou, H. Harma, A. Gaigneaux, T. N. Grossmann, D. K. Abankwa

The paper identifies a peptide that disrupts the interaction between Gal1 and B-Raf-RBD, reducing H-Ras nanoclustering and MAPK signaling in cancer cells.

bioRxiv · Sep 7, 2023 · PreprintBiochemistry

An improved PDE6D inhibitor combines with Sildenafil to synergistically inhibit KRAS mutant cancer cell growth

P. Kaya, E. Schaffner-Reckinger, G. B. Manoharan, V. Vukic, A. Kiriazis, M. Ledda, M. Burgos, K. Pavic, A. Gaigneaux, E. Glaab, D. K. Abankwa

The paper develops a novel PDE6D inhibitor, Deltaflexin3, which synergizes with Sildenafil to inhibit KRAS mutant cancer cell growth, though survival data suggest further exploration of K-Ras and PDE6D interplay.

bioRxiv · Aug 23, 2023Biochemistry

Discovery of NOvel CIP2A VAriant (NOCIVA) and its clinical relevance in myeloid leukemias

E. Makela, K. Pavic, T. Varila, U. Salmenniemi, E. Loyttyniemi, S. Nagelli, V.-M. Kahari, R. E. Clark, V. K. Bachanaboyina, C. Lucas, M. Itala-Remes, J. Westermarck

The paper discovers a novel CIP2A splicing variant, NOCIVA, which is overexpressed in myeloid leukemias and correlates with poor clinical outcomes.

bioRxiv · Aug 24, 2020Cancer Biology